Genomic Landscape of Prostate Cancer Differs by Ancestry, but Frequency of Actionable Alterations Is Similar clinicaladvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaladvisor.com Daily Mail and Mail on Sunday newspapers.
(0)
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial
SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ( Aptevo ) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR
TM and ADAPTIR-FLEX
TM platform technologies today announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia (AML) with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase (Part 1) of the study. During Part 1, APVO436 exhibited a manageable side effect profile, encouraging single agent activity and a promising benefit to risk profile in relapsed AML patients. The Company has plans to submit data from the dose escalation phase for publication later this year.
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.